Ionis (IONS) shares rise after-hours after FDA approval for Zanvastro
Ionis Pharmaceuticals shares edged up 1% after-hours Thursday after the FDA approved Zanvastro as the first treatment for Alexander disease, ahead of a stated deadline. Shares fell about 6% in regular trading after Ultragenyx reported a failed trial.